Jeremy H. Raymond
Orsay, France
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 13 publications
MICAL2 as a key effector of β-catenin signaling driving melanoma progression and therapeutic resistance.
Journal: Cell death and differentiation
Published: November 13, 2025
Publisher Correction: Targeting GRPR for sex hormone-dependent cancer after loss of E-cadherin.
Journal: Nature
Published: July 14, 2025
The Lipid Droplet Protein DHRS3 Is a Regulator of Melanoma Cell State.
Journal: Pigment cell & melanoma research
Published: May 20, 2024
The lipid droplet protein DHRS3 is a regulator of melanoma cell state.
Journal: bioRxiv : the preprint server for biology
Published: April 08, 2024
UVB radiation suppresses Dicer expression through β-catenin.
Journal: Journal of cell science
Published: January 24, 2024
Targeting GRPR for sex hormone-dependent cancer after loss of E-cadherin.
Journal: Nature
Published: October 09, 2023
Derivation and Use of Cell Lines from Mouse Models of Melanoma.
Journal: The Journal of investigative dermatology
Published: July 13, 2022
Targeting GPCRs and Their Signaling as a Therapeutic Option in Melanoma.
Journal: Cancers
Published: January 06, 2022
Efficacy of Targeted Radionuclide Therapy Using [131I]ICF01012 in 3D Pigmented BRAF- and NRAS-Mutant Melanoma Models and In Vivo NRAS-Mutant Melanoma.
Journal: Cancers
Published: December 24, 2020
CLEC12B Decreases Melanoma Proliferation by Repressing Signal Transducer and Activator of Transcription 3.
Journal: The Journal of investigative dermatology
Published: April 02, 2020
BRN2 is a non-canonical melanoma tumor-suppressor.
Journal: Nature communications
Published: April 24, 2019
Last Updated: 09/26/2026